康希诺生物绩后涨超5% 流脑结合疫苗收入保持增长 全年纯利实现扭亏为盈

Core Viewpoint - 康希诺生物 reported a significant increase in revenue and profitability, indicating a successful implementation of its innovative and commercialization strategies [1] Financial Performance - Total revenue reached 1.068 billion RMB, representing a year-on-year growth of 26.18% [1] - Net profit attributable to shareholders was 27.8727 million RMB, marking a turnaround from a loss to profitability [1] Strategic Initiatives - The company continues to focus on innovation and commercialization, with the first four-valent meningococcal vaccine, Manhaixin, contributing to sustained revenue growth [1] - Cost reduction and efficiency improvement measures have been effectively implemented, leading to better expense management [1] - The optimization of production and sales coordination has resulted in an increase in gross profit margin [1]